VIATRIS INC. Debt Issuance Cost, Gross, Noncurrent
VIATRIS INC. (VTRS) had Debt Issuance Cost, Gross, Noncurrent of $89.00 million as of 2020-09-27, per its 10-Q filed 2020-11-10.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DeferredFinanceCostsNoncurrentGross · last filed 2020-11-10
- 2020-09-27: Debt Issuance Cost, Gross, Noncurrent $89.00M.
- 2020-06-28: Debt Issuance Cost, Gross, Noncurrent $89.30M.
| Period end | Debt Issuance Cost, Gross, Noncurrent |
|---|---|
| 2020-09-27 | $89.00M 10-Q · filed 2020-11-10 |
| 2020-06-28 | $89.30M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |